Prabhudas Lilladher recommended accumulate rating on Zydus Lifesciences with a target price of Rs 970 in its research report ...

ICICI Securities recommended hold rating on Zydus Lifesciences with a target price of Rs 910 in its research report dated May ...

After a record FY25, the drugmaker sees new growth engines in biologics, vaccines, and devices powering expansion in FY26.

Zydus Lifesciences Q4 stuns with margin guidance, but brokerages trim targets — stock ends at Rs 890. Should you follow ...

Zydus Lifesciences is on analysts' radar. The stock rose nearly 2% on Wednesday after reporting mixed fourth-quarter results.

The pharma companys Board has recommended a final dividend of Rs 11 per equity share of face value Rs 1 each, representing a ...

Zydus Lifesciences consolidated net profit slipped about 1 per cent year-on-year (Y-o-Y) to ₹1,171 crore in the March quarter ...

Results: Net profit for the quarter fell 1% from the year-ago period to ₹1,171 crore. The company reported a one-time loss of ...

Zydus Lifesciences Limited announced a notable 19% increase in revenue for FY25, with net profits rising to Rs. 47,451 mn.

The consolidated net profit of Zydus Lifesciences Ltd for the fourth quarter of financial year 2025 dropped marginally to ...

Zydus Lifesciences Limited reported a significant 19% increase in revenue for FY25, reaching Rs. 2,32,415 million. The ...

Morgan Stanley believes India's fundamentals remain strong, supported by macro stability, improving terms of trade, declining ...